The present invention is directed to compounds which are allosteric
modulators of metabotropic glutamate receptors, including the mGluR5
receptor, and which are useful in the treatment of neurological and
psychiatric disorders associated with glutamate dysfunction and diseases
in which metabotropic glutamate receptors are involved. The invention is
also directed to pharmaceutical compositions comprising these compounds
and the use of these compounds and compositions in the prevention or
treatment of such diseases in which metabotropic glutamate receptors are
involved.